print page


Welcome to Palatin's Media Center Information Site. For your convenience, we provide within this section product photos, news releases, an events calendar, as well as company and product fact sheets and contact information.

Palatin at-a-Glance:

Palatin Technologies, Inc. is a biopharmaceutical company focused on discovering and developing melanocortin (MC)-based therapeutics. The Company is developing bremelanotide (formerly PT-141), a MC receptor agonist, for the treatment of male and female sexual dysfunction. Palatin’s patented drug discovery platform, MIDAS™, streamlines the drug discovery process with an efficient approach to creating lead compounds based on protein conformation.

Latest News:

Palatin Technologies Strengthens Intellectual Property Surrounding Use of Bremelanotide for Female Sexual Dysfunction
Palatin Technologies to present at the BIO CEO & Investor Conference
Palatin Technologies Achieves Target Patient Enrollment in Pivotal Phase 3 Studies for Bremelanotide for Female Sexual Dysfunction

Upcoming Events:



Portions of this website may contain forward-looking statements concerning the future business, operating results and/or financial condition of Palatin Technologies, Inc. as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations and are subject to a number of uncertainties that could cause actual performance and results to differ materially from those anticipated by such forward-looking statements. For more information about these risks, please see the documents that the Company files from time to time with the Securities and Exchange Commission. Any forward-looking statements on this website are based on current expectations, and Palatin Technologies assumes no obligation to update them.